{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:03:14Z","timestamp":1795006994938,"version":"4.9.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ceftazidime\u2013avibactam is effective and well tolerated in adults with complicated urinary tract infection (cUTI), but has not been evaluated in children with cUTI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This single-blind, multicenter, active-controlled, phase 2 study (NCT02497781) randomized children \u22653 months to &lt;18 years with cUTI (3:1) to receive intravenous (IV) ceftazidime\u2013avibactam or cefepime for \u226572 hours, with subsequent optional oral switch. Total treatment duration was 7\u201314 days. Primary objective was assessment of safety. Secondary objectives included descriptive efficacy and pharmacokinetics. A blinded observer determined adverse event (AE) causality and clinical outcomes up to the late follow-up visit (20\u201336 days after the last dose of IV\/oral therapy).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 95 children received \u22651 dose of IV study drug (ceftazidime\u2013avibactam, n = 67; cefepime, n = 28). The predominant baseline Gram-negative uropathogen was <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic> (92.2%). AEs occurred in 53.7% and 53.6% patients in the ceftazidime\u2013avibactam and cefepime groups, respectively. Serious AEs occurred in 11.9% (ceftazidime\u2013avibactam) and 7.1% (cefepime) patients. One serious AE (ceftazidime\u2013avibactam group) was considered drug related. In the microbiologic intent-to-treat analysis set, favorable clinical response rates &gt;95% were observed for both groups at end-of-IV and remained 88.9% (ceftazidime\u2013avibactam) and 82.6% (cefepime) at test-of-cure. Favorable per-patient microbiologic response at test-of-cure was 79.6% (ceftazidime\u2013avibactam) and 60.9% (cefepime).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Ceftazidime\u2013avibactam was well tolerated in children with cUTI, with a safety profile consistent with that of adults with cUTI and of ceftazidime alone, and appeared effective in children with cUTI due to Gram-negative pathogens.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002395","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T21:32:12Z","timestamp":1563744732000},"page":"920-928","source":"Crossref","is-referenced-by-count":79,"title":["Safety and Efficacy of Ceftazidime\u2013Avibactam in the Treatment of Children \u22653 Months to &lt;18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial"],"prefix":"10.1097","volume":"38","author":[{"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"From the *Rady Children\u2019s Hospital\/UCSD, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Roilides","sequence":"additional","affiliation":[{"name":"3rd Department of Pediatrics, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Broadhurst","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pfizer, Sandwich, Kent, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Min","family":"Huang","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"MasCasullo","sequence":"additional","affiliation":[{"name":"Allergan plc, Madison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Newell","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Tawadrous","sequence":"additional","affiliation":[{"name":"Pfizer, Groton, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Wajsbrot","sequence":"additional","affiliation":[{"name":"Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Yates","sequence":"additional","affiliation":[{"name":"AstraZeneca, Alderley Park, Cheshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gardner","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"176.e1","DOI":"10.1016\/j.jpurol.2017.12.002","article-title":"Changes in antimicrobial resistance and demographics of UTIs in pediatric patients in a single institution over a 6-year period.","volume":"14","author":"Erol","year":"2018","journal-title":"J Pediatr Urol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"39","DOI":"10.25100\/cm.v45i1.1318","article-title":"Resistance profile for pathogens causing urinary tract infection in a pediatric population, and antibiotic treatment response at a university hospital, 2010-2011.","volume":"45","author":"V\u00e9lez Echeverri","year":"2014","journal-title":"Colomb Med (Cali)"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.juro.2013.01.069","article-title":"Antibiotic resistance patterns of outpatient pediatric urinary tract infections.","volume":"190","author":"Edlin","year":"2013","journal-title":"J Urol"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11845-012-0834-5","article-title":"An 11-year analysis of the prevalent uropathogens and the changing pattern of Escherichia coli antibiotic resistance in 38,530 community urinary tract infections, Dublin 1999-2009.","volume":"182","author":"Cullen","year":"2013","journal-title":"Ir J Med Sci"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4065\/mcp.2010.0674","article-title":"Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.","volume":"86","author":"Kanj","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.02247-12","article-title":"Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC \u03b2-lactamases.","volume":"57","author":"Lahiri","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/phar.1622","article-title":"The \u03b2-lactams strike back: ceftazidime-avibactam.","volume":"35","author":"Zasowski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1179\/joc.2000.12.2.115","article-title":"Antibiotic prophylaxis in children with relapsing urinary tract infections: review.","volume":"12","author":"Mangiarotti","year":"2000","journal-title":"J Chemother"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fcimb.2015.00045","article-title":"Epidemiology and characteristics of urinary tract infections in children and adolescents.","volume":"5","author":"Hanna-Wakim","year":"2015","journal-title":"Front Cell Infect Microbiol"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program.","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"6252","DOI":"10.1128\/AAC.00862-16","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.","volume":"60","author":"Bradley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/00006454-199807000-00012","article-title":"Cefepine vs. ceftazidime treatment of pyelonephritis: a European, randomized, controlled study of 300 pediatric cases. European Society for Paediatric Infectious Diseases (ESPID) Pyelonephritis Study Group.","volume":"17","author":"Schaad","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study.","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"126142","DOI":"10.1155\/2014\/126142","article-title":"Bacterial pathogens and antimicrobial resistance patterns in pediatric urinary tract infections: a four-year surveillance study (2009-2012).","volume":"2014","author":"Mirsoleymani","year":"2014","journal-title":"Int J Pediatr"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.juro.2011.09.035","article-title":"Pseudomonas aeruginosa urinary tract infection in children: risk factors and outcomes.","volume":"187","author":"Bitsori","year":"2012","journal-title":"J Urol"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jinf.2016.07.014","article-title":"Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: a systematic review and meta-analysis.","volume":"73","author":"Flokas","year":"2016","journal-title":"J Infect"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2296-14-25","article-title":"Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients.","volume":"14","author":"McGregor","year":"2013","journal-title":"BMC Fam Pract"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0165-6147(81)90275-3","article-title":"Post-marketing surveillance: how many patients?","volume":"2","author":"Lewis","year":"1981","journal-title":"Trends in Pharmacological Sciences"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:54:35Z","timestamp":1694559275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002395","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}